RELA and central nervous system cancer: According to the WHO classification of glioma (as of 2016), C11orf95–RELA fusion, IDH1/2 mutation, H3-K27M mutation, and 1p/19q deletion are categorized as diagnostic biomarkers defining distinct glioma entities.